

DIRECTOR LOANS

MELBOURNE (AUSTRALIA) 29 September 2026: Invion Limited (ASX: IVX) ("Invion" or the "Company") advises that it has entered into loan agreements with Executive Chair & CEO Prof Thian Chew and Non-Executive Director Alan Yamashita, providing a combined \$400,000 in funding support for the Company's working capital requirements.

The loans reflect the continued commitment of Invion's Board to advancing the Company's clinical and operational programs.

Director Loan Overview

Invion has executed two identical loan agreements, each providing \$200,000, on the following terms:

- **Loan amount:** Up to \$200,000 per director (\$400,000 total).
- **Interest rate:** 8.0% per annum, accruing daily and payable at maturity.
- **Upfront fee:** 2.0% applied on each advance.
- **Maturity:** Four (4) months from the date of each advance.
- **Security:** Unsecured.
- **Conversion right:** The lender may elect to convert all or part of the outstanding amounts into shares at \$0.05 per share (a 26% premium to the 30-day VWAP), subject to shareholder approval.

The Company confirms that any conversion of outstanding amounts into equity would be subject to shareholder approval and full compliance with the ASX Listing Rules.

This announcement was approved for release by Invion's Board of Directors.

Sign up at Invion's Investor Hub to receive regular updates, provide feedback and participate in discussions: <https://investors.inviongroup.com/>

Investor and Media enquiries:

Thian Chew (Chairman & CEO)
T: +61 3 9692 7222
E: investor@inviongroup.com

Brendon Lau (Investor & Media Relations)
M: +61 409 341 613
E: brendon.lau@inviongroup.com

ASX ANNOUNCEMENT

About Invion

Invion is a life-science company leading global research and development of the Photosoft™ technology for the treatment of a range of cancers, atherosclerosis, and infectious diseases. Invion holds the global exclusive license to the Photosoft technology for multiple cancer and non-cancer disease indications. Invion is listed on the ASX (ASX: IVX). Find out more at www.inviongroup.com.

About Next Generation Photodynamic Therapy (NGPDT)

Invion is developing its platform Photosoft™ technology as a novel Next Generation Photodynamic Therapy (NGPDT). NGPDT uses non-toxic photosensitisers and light to selectively kill cancer cells and promote an anti-cancer immune response. Less invasive than surgery and with minimal side effects, NGPDT offers an alternative treatment option aimed at achieving complete tumour regression and long-lasting remission. NGPDT has also demonstrated potential in non-cancer disease areas including broad-spectrum activity across multiple infectious diseases, including bacteria, fungi and viruses. Photosoft has the potential to address the global challenge of antibiotic-resistant "superbugs", in addition to other indications.